文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

新型分子靶向个性化放射性药物的经济学

Economics of New Molecular Targeted Personalized Radiopharmaceuticals.
PubMed 文献 · Semin Nucl Med · 2019-01-01

本文回顾了核医学从2007年放射性药物批准低谷到当前诊疗一体化(theragnostic)兴起的转变。分子成像通过定量药物对靶点的效应和正常组织毒性,缩短筛选时间并降低成本;FDA批准Lutathera与NETSPOT及诺华收购AAA等案例显示靶向诊疗一体化放射性药物具备可行商业模式。

要点

  • 诊疗一体化利用分子诊断实时分层患者,指导药物选择、剂量与给药时机。
  • 分子成像可定量全身在体功能与患者异质性,辅助个体化治疗决策。
  • FDA已要求靶向治疗性放射性药物的临床评价采用成像来指导和监测治疗。

核心结论

  • 靶向诊疗一体化放射性药物与个性化医疗已显现可行的商业模式。

研究设计与样本

  • 本文为综述,回顾核医学放射性药物研发经济学与诊疗一体化进展。

主要发现

  • 分子成像通过定量药物对靶点的效应和正常组织毒性,减少筛选候选药物的时间与成本。
  • FDA批准Lutathera与NETSPOT后,更多制药公司推进诊疗一体化。

临床怎么用

  • 利用诊疗一体化在体定量全身功能与患者异质性,个体化选择药物、剂量与给药时机。
  • 以成像指导和监测靶向治疗性放射性药物的临床评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nuclear medicine has come a long way since 2007 when Adrian Nunn pointed out the approval of radiopharmaceuticals was at an all-time low with all the major radiopharmaceutical agents in use having been approved over 10 years ago. Challenges being the prohibitively high cost of drug development and the large number of drugs failing in clinical trials. Proceed to today where molecular imaging is fast-tracking the drug discovery process by reducing both the time and cost to screen candidates by quantitating the drugs effect on the target and toxicity to normal tissues. Nuclear medicine is now leading medical practice in personalized medicine using the theragnostic approach. Theragnostics is defined as the use of molecular diagnostic techniques in real time to stratify patients to guide treatment decisions such as the choice of drug, the dose of administration, and the timing of drug delivery for a given patient. Enabling visualization and quantitation of in vivo function of the whole body and thus patient heterogeneity and variability informs the physician on how to treat an individual patient. Recent successes such as the Food and Drug Administration approval of Lutathera and NETSPOT have resulted in an increasing number of pharmaceutical companies pursing theragnostics further heightened by the purchase of Advanced Accelerator Applications for 3.9 billion by Novartis and Endocyte, Inc for 2.1 billion. Theragnostics are further aiding drug development by showing which agents are most viable and reducing the overall cost of bringing a drug to clinical trials and regulatory approval. This is indeed a renaissance for nuclear medicine in which the acceptance of imaging to inform and monitor therapy has been embraced and even required by the Food and Drug Administration for the clinical evaluation of targeted therapeutic radiopharmaceuticals showing there is indeed a viable business model for targeted theragnostic radiopharmaceuticals and personalized medicine.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cutler CS. Economics of New Molecular Targeted Personalized Radiopharmaceuticals. Semin Nucl Med. 2019. PMID: 31470937. doi:10.1053/j.semnuclmed.2019.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。